MEVALONATE PATHWAY AND ISOPRENOIDS REGULATE HUMAN BRONCHIAL MYOCYTE PROLIFERATION

被引：21

作者：

VIGANO, T

HERNANDEZ, A

CORSINI, A

GRANATA, A

BELLONI, P

FUMAGALLI, R

PAOLETTI, R

FOLCO, G

机构：

[1] UNIV MILAN,INST PHARMACOL SCI,I-20133 MILAN,ITALY

[2] UNIV MILAN,CTR CARDIOPULM PHARMACOL,MILAN,ITALY

[3] OSPED MAGGIORE NIGUARDA,CTR GASPERIS CHIRURG TORAC,MILAN,ITALY

来源：

EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION | 1995年 / 291卷 / 02期

关键词：

HUMAN BRONCHIAL MYOCYTE; SIMVASTATIN; MEVALONATE; GERANYLGERANIOL; CELL PROLIFERATION;

D O I：

10.1016/0014-2999(95)90104-3

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The role of mevalonate and geranylgeraniol in the control of cellular proliferation of cultured human bronchial myocytes was examined by investigating the effect of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in mevalonate synthesis. Simvastatin inhibited the rate of growth of human bronchial smooth muscle cells in a concentration-dependent manner, with an IC50 value of 0.97 +/- 0.1 mu M. Mevalonate (100 mu M), as well as geranylgeraniol (5 mu M), at their highest non-toxic concentrations, restored cell proliferation to control levels.

引用

页码：201 / 203

页数：3

共 13 条

[1]

BUSSE WW, 1988, ALLERGY PRINCIPLES P, P969

[2]

CASEY PJ, 1992, J LIPID RES, V33, P1731

[3] RELATIONSHIP BETWEEN MEVALONATE PATHWAY AND ARTERIAL MYOCYTE PROLIFERATION - IN-VITRO STUDIES WITH INHIBITORS OF HMG-COA REDUCTASE [J].